{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 42 of 129', '11. Receipt of any investigational non-biologic agent within 5 half-lives prior to', 'randomisation.', '12. Receipt of blood products within 4 weeks prior to screening.', '13. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or', 'hospitalisation during the trial period.', '14. Known or suspected allergy or reaction to any component of the IMP formulation.', '15. History of any active skin infection within 1 week prior to randomisation.', '16. History of a clinically significant infection within 4 weeks prior to randomisation', \"which, in the opinion of the investigator or sponsor's medical expert, may compromise\", 'the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the', \"subject's ability to participate in the trial. Clinically significant infections are defined\", 'as:', 'A systemic infection.', 'A serious skin infection requiring parenteral (intravenous or intramuscular)', 'antibiotics, antiviral, or antifungal medication.', '17. A helminth parasitic infection within 6 months prior to the date informed consent is', 'obtained that has not been treated with, or has failed to respond to, standard of care', 'therapy.', '18. History of anaphylaxis following any biological therapy.', '19. History of immune complex disease.', '20. History of cancer:', 'Subjects who have had basal cell carcinoma, localised squamous cell', 'carcinoma of the skin or in situ carcinoma of the cervix are eligible provided', 'that the subject is in remission and curative therapy was completed at least', '12 months prior to the date informed consent was obtained.', 'Subjects who have had other malignancies are eligible provided that the', 'subject is in remission and curative therapy was completed at least 5 years', 'prior to the date informed consent was obtained.', '21. Tuberculosis requiring treatment within the 12 months prior to screening. Evaluation', 'will be according to local guidelines as per local standard of care.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 43 of 129', '22. History of any known primary immunodeficiency disorder including a positive human', 'immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral', \"medications as determined by medical history and/or subject's verbal report.\", '23. History of chronic alcohol or drug abuse within 12 months prior to screening, or any', 'condition associated with poor compliance as judged by the investigator.', '24. History of attempted suicide or is at significant risk of suicide (either in the opinion of', 'the investigator or defined as a \"yes\" to suicidal ideation questions no. 4 or 5 or', 'answering \"yes\" to suicidal behaviour on the Columbia-Suicide Severity Rating Scale', '[C-SSRS] Screening version).', '25. Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic,', 'renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological,', 'immunological, psychiatric, or major physical impairment that is not stable, in the', 'opinion of the investigator, and could:', 'Affect the safety of the subject throughout the trial.', 'Influence the findings of the trial or their interpretations.', \"Impede the subject's ability to complete the entire duration of trial.\", '26. Any clinically significant abnormal findings in physical examination, vital signs,', 'electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during the', 'screening period, which in the opinion of the investigator, may put the subject at risk', 'because of his/her participation in the trial, or may influence the results of the trial, or', \"the subject's ability to complete entire duration of the trial.\", '27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level >2.0 times', 'the ULN (upper limit of normal) at screening.', '28. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),', 'hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology', 'at screening. Subjects with positive HBsAb may be randomised provided they are', 'hepatitis B vaccinated and have negative HBsAg and HBcAb.', '29. Subjects who are not willing to abstain from donating blood and/or plasma from the', 'time of informed consent and for 16 weeks (5 half-lives) after last dose of IMP.', '30. Subjects who are legally institutionalised.', '31. Pregnant, breastfeeding, or lactating women.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}